SLC22A5 and neoplasm: This study has limitations, such as the lack of information on the impact of OCTN2 on the clinical outcome of patients with esophageal adenocarcinoma treated with oxaliplatin as well as the lack of oxaliplatin-naïve groups important to better understand the impact of OCTN2 on tumor biology.